Annual Cash & Cash Equivalents
$131.46 M
+$29.82 M+29.34%
December 31, 2023
Summary
- As of February 24, 2025, PRQR annual cash & cash equivalents is $131.46 million, with the most recent change of +$29.82 million (+29.34%) on December 31, 2023.
- During the last 3 years, PRQR annual cash & cash equivalents has risen by +$38.18 million (+40.93%).
- PRQR annual cash & cash equivalents is now -38.08% below its all-time high of $212.32 million, reached on December 31, 2021.
Performance
PRQR Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$99.85 M
+$15.20 M+17.96%
September 1, 2024
Summary
- As of February 24, 2025, PRQR quarterly cash and cash equivalents is $99.85 million, with the most recent change of +$15.20 million (+17.96%) on September 1, 2024.
- Over the past year, PRQR quarterly cash and cash equivalents has stayed the same.
- PRQR quarterly cash and cash equivalents is now -52.97% below its all-time high of $212.32 million, reached on December 31, 2021.
Performance
PRQR Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PRQR Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +29.3% | 0.0% |
| 3 y3 years | +40.9% | +1.1% |
| 5 y5 years | +8.8% | +1.1% |
PRQR Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -38.1% | +29.3% | -53.0% | +18.0% |
| 5 y | 5-year | -38.1% | +40.9% | -53.0% | +25.5% |
| alltime | all time | -38.1% | >+9999.0% | -53.0% | +1651.3% |
ProQR Therapeutics NV Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $99.85 M(+18.0%) |
| Jun 2024 | - | $84.65 M(-8.5%) |
| Mar 2024 | - | $92.56 M(-29.6%) |
| Dec 2023 | $131.46 M(+29.3%) | $131.46 M(+3.0%) |
| Sep 2023 | - | $127.60 M(-8.7%) |
| Jun 2023 | - | $139.71 M(-7.8%) |
| Mar 2023 | - | $151.56 M(+49.1%) |
| Dec 2022 | $101.64 M(-52.1%) | $101.64 M(+3.0%) |
| Sep 2022 | - | $98.71 M(-39.6%) |
| Jun 2022 | - | $163.38 M(-12.7%) |
| Mar 2022 | - | $187.08 M(-11.9%) |
| Dec 2021 | $212.32 M(+127.6%) | $212.32 M(+17.2%) |
| Sep 2021 | - | $181.11 M(+9.1%) |
| Jun 2021 | - | $165.94 M(+108.5%) |
| Mar 2021 | - | $79.57 M(-14.7%) |
| Dec 2020 | $93.28 M(-25.6%) | $93.28 M(-10.6%) |
| Sep 2020 | - | $104.31 M(+6.4%) |
| Jun 2020 | - | $98.00 M(-9.4%) |
| Mar 2020 | - | $108.16 M(-13.8%) |
| Dec 2019 | $125.40 M | $125.40 M(+53.2%) |
| Sep 2019 | - | $81.83 M(-12.7%) |
| Jun 2019 | - | $93.76 M(-11.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2019 | - | $105.65 M(-12.5%) |
| Dec 2018 | $120.77 M(+109.3%) | $120.77 M(-8.6%) |
| Sep 2018 | - | $132.14 M(+246.7%) |
| Jun 2018 | - | $38.12 M(-18.6%) |
| Mar 2018 | - | $46.85 M(-18.8%) |
| Dec 2017 | $57.70 M(-7.8%) | $57.70 M(+23.2%) |
| Sep 2017 | - | $46.82 M(-3.3%) |
| Jun 2017 | - | $48.41 M(-13.1%) |
| Mar 2017 | - | $55.69 M(-11.0%) |
| Dec 2016 | $62.58 M(-39.7%) | $62.58 M(-14.1%) |
| Sep 2016 | - | $72.83 M(-14.2%) |
| Jun 2016 | - | $84.88 M(-12.4%) |
| Mar 2016 | - | $96.86 M(-6.6%) |
| Dec 2015 | $103.72 M(-24.3%) | $103.72 M(-7.8%) |
| Sep 2015 | - | $112.53 M(-5.7%) |
| Jun 2015 | - | $119.32 M(-3.2%) |
| Mar 2015 | - | $123.25 M(-10.1%) |
| Dec 2014 | $137.09 M(+2304.4%) | $137.09 M(-6.3%) |
| Sep 2014 | - | $146.25 M(+180.7%) |
| Jun 2014 | - | $52.11 M(+813.9%) |
| Dec 2013 | $5.70 M(+1631.4%) | $5.70 M |
| Dec 2012 | $329.30 K | - |
FAQ
- What is ProQR Therapeutics NV annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ProQR Therapeutics NV?
- What is ProQR Therapeutics NV annual cash & cash equivalents year-on-year change?
- What is ProQR Therapeutics NV quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for ProQR Therapeutics NV?
- What is ProQR Therapeutics NV quarterly cash and cash equivalents year-on-year change?
What is ProQR Therapeutics NV annual cash & cash equivalents?
The current annual cash & cash equivalents of PRQR is $131.46 M
What is the all time high annual cash & cash equivalents for ProQR Therapeutics NV?
ProQR Therapeutics NV all-time high annual cash & cash equivalents is $212.32 M
What is ProQR Therapeutics NV annual cash & cash equivalents year-on-year change?
Over the past year, PRQR annual cash & cash equivalents has changed by +$29.82 M (+29.34%)
What is ProQR Therapeutics NV quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PRQR is $99.85 M
What is the all time high quarterly cash and cash equivalents for ProQR Therapeutics NV?
ProQR Therapeutics NV all-time high quarterly cash and cash equivalents is $212.32 M
What is ProQR Therapeutics NV quarterly cash and cash equivalents year-on-year change?
Over the past year, PRQR quarterly cash and cash equivalents has changed by $0.00 (0.00%)